SLC5A2 and Other metabolic disease: While the glucose-lowering, cardioprotective and renoprotective properties of SGLT2 inhibitors are well established and these drugs are widely used in clinical practice, it is not clear whether SGLT2 inhibitors are capable of preventing metabolic disease in a high-risk scenario.